Abstract
Background Whilst SARS-CoV-2 infection has become endemic, COVID-19 related hospitalization and mortality are still considerably high. Both anti-viral and immune modulating therapies against COVID-19 are available, but they must be initiated early after infection and given only to patients of need. Currently, patients’ demographics and clinical pre-conditions factors are used to determine treatment eligibility. However, the latter do not provide accurate prediction and there are no useful biomarkers for early accurate prediction of COVID-19 related hospitalization risk and disease progression.
Methods Non-vaccinated patients (N=185) were recruited early after the first positive SARS-CoV-2 test. Biochemistry, hematology and 8 serum cytokine levels were longitudinally measured within the first month.
Findings Early levels of LDH, IL-6 or CRP, each alone or their combinations, were identified as accurate predictors for the risk of hospitalization (sensitivity=93.6-100%, specificity=93.4-96.7%, p<0.0001). Moreover, the combination of 4 cytokines (IFN-α, IFN-γ, IL-6, IL-17A) was the only accurate predictor for symptoms risk (sensitivity=97.5%, specificity=92.3%, p<0.0001). In comparison, age and BMI showed significantly lower predictive values than above biomarkers. Prediction with above biomarkers was independent of sampling time (0-11 days post symptoms onset), age, gender, BMI, clinical pre-conditions or SARS-CoV-2 variant. Furthermore, the early higher levels of LDH, CRP and inflammatory cytokines in hospitalized, as compared to non-hospitalized, patients, stayed consistently higher for at least 4 weeks.
Interpretation The risk for COVID-19 hospitalization or symptoms can be accurately predicted as early as the time of the first positive SARS-CoV-2 test, with biomarkers that are feasibly measurable at point-of-testing. These findings could allow for better early personalized treatment and optimization of clinical management of COVID-19 patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Bavarian State Ministry for Science and Art Program for the funding of Corona research (Early-Opt-COVID19 project and research networks FOR-COVID and Bay-VOC), by grants from the Helmholtz Association Initiative and Networking Fund (KA1-Co-02 COVIPA to UP; KA1-Co-06 CORAERO to CH, MG and AUN), by the European Commission FET Open Grant VIROFIGHT (grant no. 899619), and by the Sanddorf foundation. Work in the Gorochov laboratory was supported by Institut National de la Sante et de la Recherche Medicale (INSERM), Sorbonne Universite, Fondation pour la Recherche Medicale (FRM), Paris, France, program Investissement d Avenir launched by the French Government and implemented by the Agence Nationale de la Recherche(ANR) (programme COFIFERON ANR-21-RHUS-08), by EU Horizon HLTH-2021-DISEASE-04UNDINE project, by Fondation pour la Recherche Medicale, Paris, France (programme Equipe FRM 2022) and by the Departement Medico-Universitairede Biologie et Genomique Medicales (DMU BioGen), APHP, Paris, France. We thank the PerForM-REACT Project (funded by the Free State of Bavaria and the European Regional Development Fund - ERDF) for use of devices and consumables. The French-German collaboration was additionally supported by the BayFrance foundation. UP received personal fees from Abbott, Abbvie, Arbutus, Gilead, GSK, Leukocare, J&J, Roche, MSD, Sanofi, Sobi and Vaccitech. UP is a co-founder and share-holder of SCG Cell Therapy. All other authors declare no conflict of interest. The study was independently designed, run, analyzed and summarized by the authors with no involvement from the funding agencies. The manuscript was written by the authors with no involvement of the funding agencies. The funding agencies did not pay for or were involved in any way of writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Technical University of Munich gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- AUC
- Area under the curve
- BMI
- Body Mass Index
- CI
- Confidence Interval
- CK
- Creatin Kinase
- CoVaKo
- Corona-Vakzin-Konsortium
- COVID
- Coronavirus Disease
- CRP
- C-reactive protein
- DPSO
- Days Post Symptom Onset
- ECMO
- Extracorporeal membaren oxygenation
- EDTA
- ethylene diamine tetraacetic acid
- EOC
- Early Opt Covid 19 Study
- IFN
- Interferon
- IL
- Interleukin
- IQR
- Interquantile Range
- J-Index
- Youden Index
- LDH
- Lactate Dehydrogenase
- MVS
- Mechanical Ventilation
- PCA
- Principal Component Analysis
- PCR
- Polymerace chain reaction
- PLT
- Platelet
- ROC
- Receiving Operator Curve
- SARS-CoV
- severe-acute-respiratory-syndrome-related coronavirus
- TNF
- Tumor necrosis factor
- WBC
- White Blood Cell
